Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England
The use of andexanet alfa varies markedly between NHS regions and between NHS trusts in England. This study is the first analysis of adoption of a new treatment using the OpenPrescribing Hospitals platform, which is expected to provide a generalizable framework for similar analyses in the future.
Authors
- Richard Croker (ORCID: https://orcid.org/0000-0002-8114-9186)
- Andrew D Brown (ORCID: https://orcid.org/0000-0002-3688-8393)
- Seb Bacon (ORCID: https://orcid.org/0000-0002-6354-3454)
- Louis Fisher (ORCID: https://orcid.org/0000-0002-0295-3812)
- Rosalind Byrne (ORCID: https://orcid.org/0000-0002-4378-8788)
- Richard J. Buka (ORCID: https://orcid.org/0000-0002-2738-6236)
- Helen J Curtis (ORCID: https://orcid.org/0000-0003-3429-9576)
- Ben Goldacre (ORCID: https://orcid.org/0000-0002-5127-4728)
- Brian MacKenna (ORCID: https://orcid.org/0000-0002-3786-9063)
- Stephen Black (ORCID: https://orcid.org/0000-0002-7621-9522)
- Christopher Wood (ORCID: https://orcid.org/0000-0001-5184-0606)
- Victoria Speed (ORCID: https://orcid.org/0000-0001-5064-9375)
Institutions
- University College Birmingham (GB)
- University of Oxford (GB)
- King's College Hospital NHS Foundation Trust (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1002/bcp.70417
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00